Recombinant human hyaluronidase-facilitated subcutaneous immunoglobulin infusion in primary immunodeficiency diseases

Immunotherapy

Volumn 9, Issue 12, 2017, Pages 1035-1050

  Wasserman, Richard L ^a  

^a Medical City Children's Hospital   (United States)

Author keywords

immunoglobulin; intravenous administration of immunoglobulin; primary immunodeficiency disease; recombinant human hyaluronidase; rHuPH20 facilitated subcutaneous infusion of IG; subcutaneous administration of immunoglobulin

Indexed keywords

HUMAN IMMUNOGLOBULIN; HYALURONIDASE PLUS RITUXIMAB; NEUTRALIZING ANTIBODY; PEGHPH 20; PEGVORHYALURONIDASE ALFA; RECOMBINANT HYALURONIDASE; RITUXIMAB; TRASTUZUMAB; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULIN; RECOMBINANT PROTEIN;

AGAMMAGLOBULINEMIA; ALLERGIC REACTION; ANTIBODY TITER; AREA UNDER THE CURVE; ASTHMA; BACTERIAL INFECTION; BIOEQUIVALENCE; BREAST CANCER; CHEST TIGHTNESS; DIARRHEA; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG TOLERABILITY; DYSPNEA; FACE EDEMA; FATIGUE; FEVER; HEADACHE; HUMAN; HYPOTENSION; IMMUNE DEFICIENCY; IMMUNOGENICITY; INFECTION PREVENTION; INFUSION RATE; INJECTION SITE DISCOMFORT; INJECTION SITE EDEMA; INJECTION SITE ERYTHEMA; INJECTION SITE INDURATION; INJECTION SITE PAIN; INJECTION SITE PRURITUS; INJECTION SITE SWELLING; MINIMUM PLASMA CONCENTRATION; NAUSEA; NONHODGKIN LYMPHOMA; NONHUMAN; PATIENT COMPLIANCE; PATIENT PREFERENCE; PRIORITY JOURNAL; RECOMMENDED DRUG DOSE; REVIEW; SOLID MALIGNANT NEOPLASM; SYSTEMIC DISEASE; UNCONSCIOUSNESS; VOMITING; ANIMAL; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; METABOLISM; PRACTICE GUIDELINE; PROCEDURES; SUBCUTANEOUS DRUG ADMINISTRATION;

ANIMALS; HUMANS; HYALURONOGLUCOSAMINIDASE; IMMUNOGLOBULINS; IMMUNOLOGIC DEFICIENCY SYNDROMES; IMMUNOTHERAPY; INFUSIONS, SUBCUTANEOUS; PRACTICE GUIDELINES AS TOPIC; RECOMBINANT PROTEINS;

EID: 85030636563     PISSN: 1750743X     EISSN: 17507448     Source Type: Journal    
DOI: 10.2217/imt-2017-0092     Document Type: Review

References (50)

1. Kobrynski L. Subcutaneous immunoglobulin therapy: a new option for patients with primary immunodeficiency diseases. Biologics 6, 277-287 (2012).
2. Modell V, Knaus M, Modell F, Roifman C, Orange J, Notarangelo LD. Global overview of primary immunodeficiencies: a report from Jeffrey Modell Centers worldwide focused on diagnosis, treatment and discovery. Immunol. Res. 60(1), 132-144 (2014).
3. Bousfiha A, Jeddane L, Al-Herz W et al. The 2015 IUIS phenotypic classification for primary immunodeficiencies. J. Clin. Immunol. 35(8), 727-738 (2015).
4. Perez EE, Orange JS, Bonilla F et al. Update on the use of immunoglobulin in human disease: a review of evidence. J. Allergy. Clin. Immunol. 139(3S), S1-S46 (2017).
5. Bousfiha AA, Jeddane L, Ailal F et al. Primary immunodeficiency diseases worldwide: more common than generally thought. J. Clin. Immunol. 33(1), 1-7 (2013).
6. Kobrynski L, Powell RW, Bowen S. Prevalence and morbidity of primary immunodeficiency diseases, United States 2001-2007. J. Clin. Immunol. 34(8), 954-961 (2014).
7. Wasserman RL. Progress in gammaglobulin therapy for immunodeficiency: from subcutaneous to intravenous infusions and back again. J. Clin. Immunol. 32(6), 1153-1164 (2012).
8. Bruton OC. Agammaglobulinemia. Pediatrics 9(6), 722-728 (1952).
9. Long AA, Denburg JA, Dent PB. Hypogammaglobulinemia: therapeutic rationale. CMAJ 137(9), 793-797 (1987).
10. Roifman CM, Levison H, Gelfand EW. High-dose versus low-dose intravenous immunoglobulin in hypogammaglobulinaemia and chronic lung disease. Lancet 1(8541), 1075-1077 (1987).
11. Yong PL, Boyle J, Ballow M et al. Use of intravenous immunoglobulin and adjunctive therapies in the treatment of primary immunodeficiencies: a working group report of and study by the Primary Immunodeficiency Committee of the American Academy of Allergy, Asthma, and Immunology. Clin. Immunol. 135(2), 255-263 (2010).
12. Orange JS, Grossman WJ, Navickis RJ, Wilkes MM. Impact of trough IgG on pneumonia incidence in primary immunodeficiency: a meta-analysis of clinical studies. Clin. Immunol. 137(1), 21-30 (2010).
13. Shabaninejad H, Asgharzadeh A, Rezaei N, Rezapoor A. A comparative study of intravenous immunoglobulin and subcutaneous immunoglobulin in adult patients with primary immunodeficiency diseases: a systematic review and meta-analysis. Expert Rev. Clin. Immunol. 12(5), 595-602 (2016).
14. Vivaglobin (immune globulin subcutaneous [human]), full prescribing information. CSL Behring GmbH, Marburg, Germany (2006).
15. Espanol T, Prevot J, Drabwell J, Sondhi S, Olding L. Improving current immunoglobulin therapy for patients with primary immunodeficiency: quality of life and views on treatment. Patient Prefer Adherence 8, 621-629 (2014).
16. Wasserman RL, Melamed I, Stein MR et al. Recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulins for primary immunodeficiency. J. Allergy Clin. Immunol. 130(4), 951 e911-957 e911 (2012).
17. Duran-Reynals F. The effect of extracts of certain organs from normal and immunized animals on the infecting power of vaccine virus. J. Exp. Med. 50(3), 327-340 (1929).
18. Frost GI. Recombinant human hyaluronidase (rHuPH20): an enabling platform for subcutaneous drug and fluid administration. Expert Opin. Drug Deliv. 4(4), 427-440 (2007).
19. Bookbinder LH, Hofer A, Haller MF et al. A recombinant human enzyme for enhanced interstitial transport of therapeutics. J. Control. Rel. 114(2), 230-241 (2006).
20. Lathrop WF, Carmichael EP, Myles DG, Primakoff P. cDNA cloning reveals the molecular structure of a sperm surface protein, PH-20, involved in sperm-egg adhesion and the wide distribution of its gene among mammals. J. Cell Biol. 111(6 Pt 2), 2939-2949 (1990).
21. Suez D, Stein M, Gupta S et al. Efficacy, safety and pharmacokinetics of a novel human immune globulin subcutaneous, 20% in patients with primary immunodeficiency diseases in North America. J. Clin. Immunol. 36(7), 700-712 (2016).
22. Borte M, Krivan G, Derfalvi B et al. Efficacy, safety, tolerability and pharmacokinetics of a novel human immune globulin subcutaneous, 20%: a Phase II/III study in Europe in patients with primary immunodeficiencies. Clin. Exp. Immunol. 187(1), 146-159 (2017).
23. Thompson CB, Shepard HM, O'Connor PM et al. Enzymatic depletion of tumor hyaluronan induces antitumor responses in preclinical animal models. Mol. Cancer Ther. 9(11), 3052-3064 (2010).
24. Kang DW, Jadin L, Nekoroski T, Drake FH, Zepeda ML. Recombinant human hyaluronidase PH20 (rHuPH20) facilitates subcutaneous infusions of large volumes of immunoglobulin in a swine model. Drug Deliv. Transl. Res. 2(4), 254-264 (2012).
25. Baker MP, Reynolds HM, Lumicisi B, Bryson CJ. Immunogenicity of protein therapeutics: the key causes, consequences and challenges. Self Nonself 1(4), 314-322 (2010).
26. Rosengren S, Dychter SS, Printz MA et al. Clinical immunogenicity of rHuPH20, a hyaluronidase enabling subcutaneous drug administration. AAPS J. 17(5), 1144-1156 (2015).
27. Zhou C, Kang W, Baba T. Functional characterization of double-knockout mouse sperm lacking SPAM1 and ACR or SPAM1 and PRSS21 in fertilization. J. Reprod. Dev. 58(3), 330-337 (2012).
28. Hardy CM, Clydesdale G, Mobbs KJ et al. Assessment of contraceptive vaccines based on recombinant mouse sperm protein PH20. Reproduction 127(3), 325-334 (2004).
29. Pomering M, Jones RC, Holland MK, Blake AE, Beagley KW. Restricted entry of IgG into male and female rabbit reproductive ducts following immunization with recombinant rabbit PH-20. Am. J. Reprod. Immunol. 47(3), 174-182 (2002).
30. Baba D, Kashiwabara S, Honda A et al. Mouse sperm lacking cell surface hyaluronidase PH-20 can pass through the layer of cumulus cells and fertilize the egg. J. Biol. Chem. 277(33), 30310-30314 (2002).
31. Veneziale RW, Printz MA, Jorge M et al. Nonclinical studies to assess possible effects of antibodies to rHuPH20 on the endogenous counterpart. Presented at: 16th Bienniel Meeting of the European Society for Immunodeficiencies.Prague, Czech Republic, 29 October-1 November, 2014.
32. Rosengren S, Huang L, Jadin L et al. Antibodies to recombinant human hyaluronidase (rHuPH20) in PID subjects treated with HyQvia are qualitatively similar to those in a subset of the normal healthy population. Presented at: 16th Biennial Meeting of the European Society for Immunodeficiencies. Prague, Czech Republic, 29 October-1 November 2014 (Poster 199).
33. Wasserman RL. Overview of recombinant human hyaluronidase-facilitated subcutaneous infusion of IgG in primary immunodeficiencies. Immunotherapy 6(5), 553-567 (2014).
34. Shpilberg O, Jackisch C. Subcutaneous administration of rituximab (MabThera) and trastuzumab (Herceptin) using hyaluronidase. Br. J. Cancer 109(6), 1556-1561 (2013).
35. Hamizi S, Freyer G, Bakrin N et al. Subcutaneous trastuzumab: development of a new formulation for treatment of HER2-positive early breast cancer. Onco Targets Ther. 6, 89-94 (2013).
36. Davies A, Merli F, Mihaljevic B et al. Efficacy and safety of subcutaneous rituximab versus intravenous rituximab for first-line treatment of follicular lymphoma (SABRINA): a randomized, open-label, Phase III trial. Lancet Haematol. 4(6), e272-e282 (2017).
37. Misbah S, Sturzenegger MH, Borte M et al. Subcutaneous immunoglobulin: opportunities and outlook. Clin. Exp. Immunol. 158(Suppl. 1), 51-59 (2009).
38. Wasserman RL, Melamed I, Kobrynski L et al. Efficacy, safety and pharmacokinetics of a 10% liquid immune globulin preparation (GAMMAGARD LIQUID, 10%) administered subcutaneously in subjects with primary immunodeficiency disease. J. Clin. Immunol. 31(3), 323-331 (2011).
39. Wasserman RL, Melamed I, Stein MR et al. Long-term tolerability, safety and efficacy of recombinant human hyaluronidase-facilitated subcutaneous infusion of human immunoglobulin for primary immunodeficiency. J. Clin. Immunol. 36(6), 571-582 (2016).
40. Bonagura VR, Marchlewski R, Cox A, Rosenthal DW. Biologic IgG level in primary immunodeficiency disease: the IgG level that protects against recurrent infection. J. Allergy Clin. Immunol. 122(1), 210-212 (2008).
41. Lucas M, Lee M, Oksenhendler E, Chapel H. The ratio of mean daily IgG increment/mean daily dose in immunoglobulin replacement therapy in primary antibody deficiencies. J. Allergy Clin. Immunol. Pract. 3(6), 998 e1002-1000 e1002 (2015).
42. Dumas T, Numerof R, Pierre V, Gelmont D, Yel L. Population pharmacokinetic simulations to address time to reach steady state of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (IG) (IGHy) in IG-nave patients with primary immunodeficiency diseases (PIDD) Presented at: Clinical Immunology Society Annual Meeting. Boston, MA, USA, 14-17 April 2016.
43. US Department of Health and Human Services, US Food and Drug Administration, Center for Biologics Evaluation and Research. Guidance for industry: safety, efficacy and pharmacokinetic studies to support marketing of immune globulin intravenous (human) as replacement therapy for primary humoral immunodeficiency. www.fda.gov/biologicsbloodvaccines/guidancecomplianceregulatoryinformation/guidances/blood/ucm072130.htm
44. Wasserman RL, Melamed I, Kobrynski L et al. Recombinant human hyaluronidase facilitated subcutaneous immunoglobulin treatment in pediatric patients with primary immunodeficiencies: long-term efficacy, safety and tolerability. Immunotherapy 8(10), 1175-1186 (2016).
45. Yocum RC, Kennard D, Heiner LS. Assessment and implication of the allergic sensitivity to a single dose of recombinant human hyaluronidase injection: a double-blind, placebo-controlled clinical trial. J. Infus. Nurs. 30(5), 293-299 (2007).
46. Berger M. Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDD. J. Clin. Immunol. 31(5), 924-926 (2011).
47. Rosenbach KP, Rabbat CJ, Rozen L, Hughes SM. Real-world use of recombinant human hyaluronidase-facilitated subcutaneous infusion of immunoglobulin (IGHy; HYQVIA) in patients with primary immunodeficiency disorders (PIDD). Presented at: Clinical Immunology Society Boston, MA, USA, 14-17 April 2016.
48. Gruenemeier P, Ernst C, Palagashvili T, Duff K. Retrospective review of needle length and clinical considerations during hyaluronidase-facilitated subcutaneous administration of immunoglobulin (IgHy). Presented at: American College of Allergy, Asthma & Immunology. San Francisco, CA, USA, 10-14 November 2016 (Poster 259).
49. Gruenemeier P, Ernst C, White C, Duff K. Real-world pediatric experience with hyaluronidase-facilitated subcutaneous immunoglobulin (IGHY) infusion parameters. Ann. Allergy Asthma Immunol. 117(5), S98 (2016).
50. Wasserman RL, Ito D, Xiong Y, Ye X, Bonnet P, Li-McLeod J. Impact of site of care on infection rates among patients with primary immunodeficiency diseases receiving intravenous immunoglobulin therapy. J. Clin. Immunol. 37(2), 180-186 (2017).